Nicotinic acetylcholine receptor ligands

Compounds of general formula (I) act as selective α7nAChR agonists, addressing the issue of side effects in CNS treatments by targeting the central nervous system without impacting cardiovascular and skeletal muscle sites, effectively treating cough and inflammation.

CN119095848APending Publication Date: 2024-12-06PHILIP MORRIS PRODUCTS SA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380037006.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-05-05
Filing Date
2023-04-28
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing nicotinic compounds used to treat CNS conditions induce adverse side effects at cardiovascular and skeletal muscle sites, necessitating the development of compounds that can affect CNS function without significant activity at these sites.

Method used

Development of compounds of general formula (I) or their pharmaceutically acceptable salts, which are selective α7nAChR agonists, designed to target the central nervous system without affecting other nicotinic receptor subtypes, thereby reducing side effects.

Benefits of technology

The compounds effectively inhibit cough response and provide anti-inflammatory effects in lung diseases, demonstrating reduced side effects and improved efficacy in treating conditions like acute and chronic cough, acute lung injury, and Gram-negative bacterial infections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119095848A_ABST
    Figure CN119095848A_ABST
Patent Text Reader

Abstract

Compounds of general formula (I), pharmaceutical compositions comprising said compounds, uses of said compositions and methods of making said compounds are disclosed. The compounds are nicotinic acetylcholine receptor (nAChR) ligands and can be used to prevent and / or inhibit cough. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Background Art

[0001] Nicotinic acetylcholine receptors (nAChRs) have been extensively studied for their functions in peripheral and central neurons, where they play a role in regulating neurotransmission. Several subtypes of nAChRs, commonly associated with the central nervous system (CNS), have been demonstrated to exist. The most common nAChR subtypes are the α4β2 and α7 subtypes. The α7 nAChR belongs to the family of acetylcholine-gated cation channels and exhibits different biophysical and pharmacological properties relative to other nAChR subtypes.

[0002] Although these receptors are mainly expressed in neuronal tissue, several types of immune cells also express α7nAChRmRNA. Examples of such immune cells expressing α7nAChR mRNA include macrophages, T-cells, B-cells, microglia, monocytes, and dendritic cells. The immune response to prevent excessive inflammation can be regulated by the CNS through the cholinergic anti-inflammatory pathway in which acetylcholine is released from the vagus nerve. Therefore, acetylcholine activates the postsynaptic α7nAChR of the innervated tissue (including the splenic nerve) after its stimulation and then inhibits inflammatory cytokines.

[0003] Various nicotinic compounds are known to interact with α7 nAChR and have therefore been proposed for therapeutic use. However, a disadvantage of these known nicotinic compounds is that they are associated with various adverse side effects, for example by stimulating muscle and ganglion receptors.

[0004] There is a need for compounds, compositions and methods for preventing or treating various illnesses or conditions, such as CNS conditions, including alleviating the symptoms of these conditions without associated side effects. More specifically, there is a need for compounds, compositions and methods that will affect CNS function without significantly affecting those nicotinic receptor subtypes that may induce adverse side effects, such as significant activity at cardiovascular and skeletal muscle sites. Summary of the invention

[0005] According to one aspect of the present invention, there is provided a compound of general formula (I):

[0006]

[0007] or a pharmaceutically acceptable salt thereof,

[0008] Where R 1 and R 2 each is an optionally substituted aryl group which may be the same or different, wherein one or both aryl groups contain a carbocyclic or heterocyclic aromatic ring and wherein one or both aryl groups are monocyclic or polycyclic,

[0009] And where R 1 and R2 It is optionally fused.

[0010] According to another aspect of the present invention, there is provided a compound of general formula (I):

[0011]

[0012] or a pharmaceutically acceptable salt thereof,

[0013] in:

[0014] R 1 is optionally substituted aryl or optionally substituted heteroaryl; and

[0015] R 2 is halogen, triflate, optionally substituted aryl, optionally substituted heteroaryl or absent;

[0016] or where R 1 and R 2 Together they form an optionally substituted aryl or an optionally substituted heteroaryl.

[0017] Also provided is a pharmaceutical composition comprising a compound of general formula (I), the use of a compound of general formula (I), the use of a composition comprising a compound of general formula (I) and a process for the manufacture of a compound of general formula (I), as defined in the accompanying independent claims to which reference should now be made. Preferred or advantageous features of the invention are set out in the dependent claims and are further described below.

[0018] The compounds of general formula (I) of the present invention advantageously affect the central nervous system without inducing potential adverse side effects at nicotinic receptor subtypes. These potential adverse side effects may include significant activity at cardiovascular and skeletal muscle sites.

[0019] More specifically, the compounds of general formula (I) of the present invention are α7nAChR agonists, which provide a novel non-anesthetic treatment method for patients with acute and chronic cough. As described below, the potential application of selective α7nAChR agonists as antitussives according to the present invention was confirmed in an in vivo experiment by inhibiting the cough response induced by citric acid in guinea pigs.

[0020] Additionally, α7nAChR agonists as described herein may be beneficial in the treatment of the source of cough. In preclinical studies of lung disease, α7nAChR agonists have demonstrated anti-inflammatory effects in models of acute lung injury, allergen challenge, and Gram-negative bacterial infection.

[0021] According to one aspect of the present invention, there is provided a compound of general formula (I):

[0022]

[0023]

[0024] or a pharmaceutically acceptable salt thereof. 1 and R 2 may each be an optionally substituted aryl group which may be the same or different, wherein one or both aryl groups may contain a carbocyclic or heterocyclic aromatic ring and wherein one or both aryl groups may be monocyclic or polycyclic, and wherein R 1 and R 2 May be optionally fused.

[0025] According to another aspect of the present invention, there is provided a compound of general formula (I):

[0026]

[0027] or a pharmaceutically acceptable salt thereof. 1 R may be an optionally substituted aryl group or an optionally substituted heteroaryl group. 2 R may be halogen, triflate, optionally substituted aryl, optionally substituted heteroaryl, or may be absent. 1 and R 2 Together they may form an optionally substituted aryl or an optionally substituted heteroaryl.

[0028] As used herein, the term "halo" or "halogen" refers to any radical of fluorine, chlorine, bromine or iodine.

[0029] As used herein, the term "aryl" refers to a monocyclic, bicyclic or tricyclic aromatic group containing 6 to 14 carbon atoms in the ring. Common aryl groups include C6-C 14 Aryl, for example, C6-C 10 Aryl. C6-C 14 Non-limiting examples of aryl groups include phenyl, naphthyl, phenanthrenyl, anthracenyl, indenyl, azulenyl, biphenyl, biphenylenyl, and fluorenyl groups. An "optionally substituted aryl" group may include substituents as described herein.

[0030] As used herein, the term "heteroaryl" refers to an aromatic group having 5 to 14 ring atoms (e.g., 5 to 10 ring atoms) and containing carbon atoms and 1, 2 or 3 oxygen, nitrogen or sulfur heteroatoms. Examples of heteroaryl groups include thienyl (thiophenyl), benzo [b] thienyl, naphtho [2,3-b] thienyl, thianthrenyl, furyl (furyl) , benzofuranyl, isobenzofuranyl, chromenyl, xanthenyl, dibenzothioxanthane, pyrrolyl (including but not limited to 2H-pyrrolyl), imidazolyl, pyrazolyl, triazolyl, tetrazolyl, pyridyl (pyr idyl / pyridinyl) (including but not limited to 2-pyridyl, 3-pyridyl and 4-pyridyl), pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, tetrazinyl, indolizinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl, 4H-quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinozalinyl, cinnolinyl, pteridinyl, carbazolyl, β-carbolinyl, phenanthridinyl, acridinyl, The term "optionally substituted heteroaryl" refers to an alkyl, aryl, pyridinyl, phenanthroline, phenazinyl, isothiazolyl, phenothiazinyl, isoxazolyl, furazanyl and phenoxazinyl. In the case where the heteroaryl group contains a nitrogen atom in the ring, such a nitrogen atom may be in the form of an N-oxide, for example, pyridinyl N-oxide, pyrazinyl N-oxide and pyrimidinyl N-oxide. An "optionally substituted heteroaryl" group may include substituents as described herein.

[0031] Optionally, the or each aromatic ring of the carbocyclic or heterocyclic aromatic ring of one or two aryl groups of general formula (I), the aryl of the optionally substituted aryl of general formula (I), and the heteroaryl of the optionally substituted heteroaryl of general formula (I) are 3- to 10-membered rings, such as 5- to 10-membered rings. For example, the or each aromatic ring of the carbocyclic or heterocyclic aromatic ring of one or two aryl groups of general formula (I), the aryl of the optionally substituted aryl of general formula (I), and the heteroaryl of the optionally substituted heteroaryl of general formula (I) can be 3-, 4-, 5-, 6-, 7-, 8-, 9- or 10-membered rings.

[0032] Optionally, one or two aryl groups of formula (I) and each aryl or heteroaryl group of formula (I) are monocyclic. For example, one or two aryl groups of formula (I) and each aryl or heteroaryl group of formula (I) can be independently selected from: phenyl, furanyl, pyrrolyl, thienyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, oxazolyl, oxadiazolyl, isoxazolyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl and thiadiazolyl. In one embodiment, R 1 Does not include phenyl.

[0033] Optionally, one or two aryl groups of formula (I) and each aryl or heteroaryl group of formula (I) are polycyclic. For example, one or two aryl groups of formula (I) and each aryl or heteroaryl group of formula (I) can be independently selected from: naphthyl, anthracenyl, indolizinyl, indolyl, isoindolyl, benzofuranyl, benzothienyl, benzodioxolanyl, indazolyl, pyrrolopyridinyl, benzimidazolyl, benzothiazolyl, benzisothiazolyl, purinyl, thienopyrazinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, carbazolyl, acridinyl, naphthyridinyl, phenazinyl, phenothiazinyl, phenoxazinyl and azulenyl.

[0034] Optionally, one or two aryl groups of formula (I) and each aryl or heteroaryl group of formula (I) are independently selected from the group consisting of acenaphthylene, acetylphenol anthracene, acridine, anthracene, anthracene, 9,10-anthracene dione, 9(10H)-anthraquinone, anthraquinone, anthraquinone, benzo[e]acetylphenol anthracene, benzo[c]acridine, benz[a]anthracene, 7H-benzo[de]anthracen-7-one, benzanthrone, benzo[b] Benzo[c] Benzo[g] Benzo[c]cinnoline, benzo[a]dibenzothiophene, benzo[b]fluoranthene, benzo[ghi]fluoranthene, benzo[j]fluoranthene, benzo[k]fluoranthene, 11H-benzo[a]fluorene, 11H-benzo[b]fluorene, 7H-benzo[c]fluorene, benzo[h]naphtho[1,2-f]quinoline (quinolene), benzo[b]naphtho[2,1-d]thiophene, benzo[rst]pentaphene, benzo[ghi]perylene, benzo[c]phenanthrene, benzo[a]pyrene, benzo[e]pyrene, benzo[f]quinoline, benzo[h]quinoline, benzo[b]triphenylene, diphenylene, 9H-carbazole, Coronet, 4H-cyclopenta[def]phenanthrene, cyclopenta[cd]pyrene, dibenzo[a,h]acridine, dibenzo[a,j]acridine, dibenzo[c,h]acridine, dibenzo[a,c]anthracene, dibenzo[a,h]anthracene, dibenzo[a,j]anthracene, 7H-dibenzo[a,g]carbazole, 13H-dibenzo[a,i]carbazole, 7H-dibenzo[c,g]carbazole, dibenzo[b,def] dibenzo[def,mno] Dibenzo[def,p] Dibenzo[b,h]phenanthrene, dibenzo[a,e]pyrene, dibenzo[a,h]pyrene, dibenzo[a,i]pyrene, dibenzo[a,1]pyrene, dibenzothiophene, fluoranthene, 9H-fluorene, 9H-fluoren-9-one, indeno[1,2,3-cd]pyrene, 1H-indole, isoquinoline, tetracene, naphthalene, naphtho[1,2,3,4-def] naphtho[2,3-f]quinoline, pentaphene, perylene, 1H-phenalene, phenanthrenequinone, phenanthrene, 9,10-phenanthrenedione, phenanthridine, 1,10-phenanthroline, phenanthro[4,5-bcd]thiophene, phenazine, phenazone, phenanthroline, pyrene, quinoline, triphenylene, and 9H-xanthene.

[0035] Optionally, one or two aryl groups of formula (I) and each aryl or heteroaryl group of formula (I) is substituted, for example, by 1, 2 or 3 substituents.

[0036] Optionally, substituents are independently selected from: alkyl, alkenyl, heterocyclyl, cycloalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, halogen (e.g., F, Cl, Br or I), --OR', --NR'R", --CF3, --CN, --NO2, --SR', --N3, --C(=O)NR'R", --NR'C(=O)R", --C(=O)R', --C(=O)OR', --OC(=O)R', --O(CR'R"), --C(=O)R', --SO2R' and --SO2NR'R", wherein R' and R" are each hydrogen, lower alkyl. Lower alkyl can be methyl, ethyl, propyl, isopropyl, butyl or tert-butyl. For example, the substituent may be a straight or branched chain alkyl group, including C1-C8, preferably C1-C5, such as methyl, ethyl or isopropyl, a cycloalkyl group, a heterocyclyl group, an aryl group or an arylalkyl group (such as benzyl).

[0037] Optionally, R' and R" combine to form a cyclic functional group.

[0038] Optionally, substituents are independently selected from the group consisting of cyano, halogen, alkyl, haloalkyl, cycloalkyl, alkoxy, haloalkoxy, and alkylthio.

[0039] Optionally, R of the general formula (I) 1 Selected from: 1,3,4-thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl.

[0040] Optionally, R of the general formula (I) 2 Selected from indolyl, benzofuranyl, benzothiazolyl and phenyl.

[0041] Optionally, R of the general formula (I) 1 and R 2 Therefore, R of the general formula (I) 1 and R 2 may be bonded together to form an optionally substituted aryl group. 1 and R 2 They may be taken together to form a carbocyclic or heterocyclic aromatic ring. 1 and R2 They can form a monocyclic or polycyclic group together. 1 and R 2 They may be taken together to form a 5-membered ring, a 6-membered ring, a 7-membered ring, an 8-membered ring, a 9-membered ring, a 10-membered ring, an 11-membered ring, a 12-membered ring, a 13-membered ring, a 14-membered ring, a 15-membered ring, a 16-membered ring, or a 17-membered ring.

[0042] Optionally, one or both aryl groups of general formula (I) may comprise a carbocyclic or heterocyclic aromatic ring. Optionally, one or both aryl groups of general formula (I) may be an optionally substituted carbocyclic or heterocyclic aromatic ring.

[0043] Optionally, R of the general formula (I) 1 and R 2 can together form an optionally substituted aryl group or an optionally substituted heteroaryl group. In this case, R 1 and R 2 may be independently an optionally substituted aryl group or an optionally substituted heteroaryl group. 1 and R 2 may be bonded together to form an optionally substituted aryl group or an optionally substituted heteroaryl group. 1 and R 2 They can form a monocyclic or polycyclic group together. 1 and R 2 They may be taken together to form a 5-membered ring, a 6-membered ring, a 7-membered ring, an 8-membered ring, a 9-membered ring, a 10-membered ring, an 11-membered ring, a 12-membered ring, a 13-membered ring, a 14-membered ring, a 15-membered ring, a 16-membered ring, or a 17-membered ring.

[0044] Optionally, the compound is selected from:

[0045] 4-(3-pyridinyl)-1-azabicyclo[3.2.2]non-3-ene;

[0046] 4-(6-phenyl-3-pyridyl)-1-azabicyclo[3.2.2]non-3-ene; and

[0047] 4-(6-Phenylpyridazin-3-yl)-1-azabicyclo[3.2.2]non-3-ene.

[0048] Advantageously, 4-(6-phenyl-3-pyridinyl)-1-azabicyclo[3.2.2]non-3-ene significantly reduced citric acid-induced cough counts when compared to saline controls.

[0049] Furthermore, 4-(6-phenyl-3-pyridinyl)-1-azabicyclo[3.2.2]non-3-ene also showed significant improvement in cough latency at doses approximately 20 to 30 times lower than codeine, which is considered the "gold standard" narcotic cough suppressant.

[0050] Therefore, in a preferred embodiment of the present invention, provided is: 4-(6-phenyl-3-pyridyl)-1-azabicyclo[3.2.2]non-3-ene or a pharmaceutically acceptable salt thereof.

[0051] In a preferred embodiment of the present invention, there is provided a compound of the following formula or a pharmaceutically acceptable salt thereof:

[0052]

[0053] Optionally, the pharmaceutically acceptable salt is selected from one or more of the following: chloride, bromide, sulfate, phosphate and nitrate; organic acid addition salts such as acetate, galactarate, propionate, succinate, lactate, glycolate, malate, tartrate, citrate, maleate, fumarate, methanesulfonate, p-toluenesulfonate, ascorbate; salts with acidic amino acids, for example aspartate or glutamate, or hydrates or ethanol solvates.

[0054] Optionally, the compound of general formula (I) can exist in unsolvated form and solvated form, including hydrated form. "Hydrate" refers to a complex formed by the combination of water molecules with molecules or ions of a solute. "Solvate" refers to a complex formed by the combination of solvent molecules with molecules or ions of a solute. The solvent can be an organic compound, an inorganic compound, or a mixture of the two. Solvates are intended to include hydrates. Some examples of solvents include, but are not limited to, methanol, acetonitrile, N,N-dimethylformamide, tetrahydrofuran, dimethyl sulfoxide, and water. In general, solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention. Optionally, the compound of general formula (I) can exist as a solid material, for example, in a variety of crystalline or amorphous forms. In general, all physical forms are equivalent for the purposes contemplated by the present invention and are intended to be within the scope of the present invention.

[0055] "Tautomer" means a compound resulting from a phenomenon in which a proton of one atom of a molecule is transferred to another atom (see Jerry March, Advanced Organic Chemistry: Reactions, Mechanisms and Structures, Fourth Edition, John Wiley & Sons, pp. 69-74 (1992)). Tautomer also refers to one of two or more structural isomers that are in equilibrium and are easily converted from one isomeric form to another. The compounds described herein may have one or more tautomers and therefore include various isomers. All such isomeric forms of these compounds are expressly included in the present invention.

[0056] "Isomer" means a compound with the same molecular formula but different bonding properties or order of its atoms or the arrangement of its atoms in space. Isomers whose atoms are arranged differently in space are called "stereoisomers". "Stereoisomers (stereoisomer and stereoisomers)" refer to compounds that exist in different stereoisomeric forms when they have one or more asymmetric centers or have asymmetrically substituted double bonds, and can therefore be produced as individual stereoisomers or as a mixture. Stereoisomers include enantiomers and diastereomers. Stereoisomers that are not mirror images of each other are called "diastereomers", and stereoisomers that are non-superimposable mirror images of each other are called "enantiomers". When a compound has an asymmetric center, for example, when it is bonded to four different groups, a pair of enantiomers is possible. Enantiomers can be characterized by the absolute configuration of their asymmetric centers and are described by the R- and S- ordering rules of Cahn and Prelog, or described by the way in which the molecule rotates the plane of polarized light and is designated as right-handed or left-handed (i.e., (+)- or (-)-isomers, respectively). Chiral compounds can exist as individual enantiomers or as mixtures thereof. A mixture containing equal proportions of enantiomers is referred to as a "racemic mixture". Unless otherwise indicated, the description is intended to include individual stereoisomers as well as mixtures. Methods for determining stereochemistry and separating stereoisomers are well known in the art (see Advanced Organic Chemistry, 6th edition, J. March, John Wiley and Sons, New York, 2007, Chapter 4, discussion), differing in the chirality of one or more stereocenters.

[0057] The present invention also encompasses isotopically-labeled compounds which are identical to the compounds described herein except that one or more atoms are replaced by atoms having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as but not limited to 2 H (deuterium, D), 3 H (tritium), 11 C. 13 C. 14 C. 15 N. 18 F. 31 P. 32 P. 35 S. 36 Cl and 125 I. Unless otherwise indicated, when a position is specifically designated as "H" or "hydrogen", that position is understood to have hydrogen or its isotope, such as deuterium (D) or tritium ( 3 H). Certain isotopically labeled compounds of the present invention (e.g., 3 H and 14 C-labeled) can be used in compound and / or substrate tissue distribution assays. 3 H) and carbon-14 (i.e., 14 C) and fluorine-18 (i.e., 18 F) isotopes are useful because of their ease of preparation and their detectability. In addition, heavier isotopes such as deuterium (i.e., 2 H) may offer certain therapeutic advantages due to greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and thus may be preferred in some circumstances. Isotopically labeled compounds of the present invention can generally be prepared by following procedures analogous to those described herein by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.

[0058] According to the present invention, a pharmaceutical composition comprising a compound described herein and a pharmaceutically or therapeutically acceptable excipient or carrier is also provided, for example, a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically or therapeutically acceptable excipient or carrier. For example, the pharmaceutical composition may comprise 4-(6-phenyl-3-pyridyl)-1-azabicyclo[3.2.2]non-3-ene or a pharmaceutically acceptable salt thereof.

[0059] Pharmaceutically acceptable excipients or carriers may include fillers, binders, disintegrants, glidants, lubricants, complexing agents, solubilizers and surfactants, which may be selected to facilitate administration of the compound by a particular route. Examples of carriers include calcium carbonate, calcium phosphate, various sugars such as lactose, glucose or sucrose, starch types, cellulose derivatives, gelatin, lipids, liposomes, nanoparticles, etc. Carriers also include physiologically compatible liquids as solvents or for suspensions, including, for example, sterile solutions of water for injection (WFI), saline solutions, dextrose solutions, Hank's solutions, Ringer's solutions, vegetable oils, mineral oils, animal oils, polyethylene glycols, liquid paraffin, etc. Excipients can also include, for example, colloidal silicon dioxide, silica gel, talc, magnesium silicate, calcium silicate, sodium aluminosilicate, magnesium trisilicate, powdered cellulose, macrocrystalline cellulose, carboxymethyl cellulose, croscarmellose sodium, sodium benzoate, calcium carbonate, magnesium carbonate, stearic acid, aluminum stearate, calcium stearate, magnesium stearate, zinc stearate, sodium stearyl fumarate, syloid, stearowet C, magnesium oxide, starch, sodium starch glycolate, glyceryl monostearate, glyceryl dibehenate, glyceryl palmitostearate, hydrogenated vegetable oil, hydrogenated cottonseed oil, castor seed oil, mineral oil, polyethylene glycol (e.g., PEG 400 or PEG 4000-8000), polyoxyethylene glycol, poloxamer, povidone, crospovidone, crosslinked sodium carboxymethylcellulose, alginic acid, casein, divinylbenzene methacrylate copolymer, docusate sodium, cyclodextrin (e.g., 2-hydroxypropyl-.delta.-cyclodextrin), polysorbate (e.g., polysorbate 80), cetyltrimethylammonium bromide, TPGS (d-α-tocopheryl polyethylene glycol 1000 succinate), magnesium lauryl sulfate, sodium lauryl sulfate, polyethylene glycol ethers, di-fatty acid esters of polyethylene glycol or polyoxyalkylene sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan esters ), polyoxyethylene sorbitan fatty acid esters, sorbitan fatty acid esters (e.g., sorbitan fatty acid esters from fatty acids such as oleic acid, stearic acid or palmitic acid), mannitol, xylitol, sorbitol, maltose, lactose, lactose monohydrate or spray-dried lactose, sucrose, fructose, calcium phosphate, calcium hydrogen phosphate, tricalcium phosphate, calcium sulfate, dextrates, dextran, dextrin, dextrose, cellulose acetate, maltodextrin, polydimethylsiloxane, polydextrosem, chitosan, gelatin, HPMC (hydroxypropyl methylcellulose), HPC (hydroxypropyl cellulose), hydroxyethyl cellulose, etc.

[0060] According to the present invention, there is also provided a compound described herein for use in treating a disease or condition, for example, a compound of formula (I) for use in treating a disease or condition. For example, 4-(6-phenyl-3-pyridyl)-1-azabicyclo[3.2.2]non-3-ene or a pharmaceutically acceptable salt thereof can be used to treat a disease or condition.

[0061] According to the present invention, there is also provided a compound described herein for use in treating a disease or condition mediated by an α7 nicotinic acetylcholine receptor (nAChR), for example, a compound of formula (I) for treating a disease or condition mediated by an α7 nicotinic acetylcholine receptor (nAChR). For example, 4-(3-pyridyl)-1-azabicyclo[3.2.2]non-3-ene or a pharmaceutically acceptable salt thereof can be used to treat a disease or condition mediated by an α7 nicotinic acetylcholine receptor (nAChR).

[0062] Advantageously, the compounds described herein, such as compounds of formula (I), competitively inhibit the binding of radiolabeled α-bungarotoxin to human α7nAChR subtype, with an equilibrium constant (Ki) value of 1-1000 nM. Therefore, the compounds described herein, such as compounds of formula (I), are suitable for treating diseases or conditions mediated by α7 nicotinic acetylcholine receptors (nAChR).

[0063] The expression "mediated", such as "mediated by nAChR", is understood to mean associated with the activity of nAChR.

[0064] For example, the expression "mediated" may be understood to mean "controlled by", such as "transcriptional or translational control", or "transcriptional or translational regulation", such as up-regulation or down-regulation. Preferably, the expression "mediated by nAChR" may be understood to be related to the activation (i.e., opening) of the nAChR ion channel. More specifically, conformational changes in the nAChR ion channel may occur upon binding of the compound, resulting in a distortion of the quaternary symmetry of the M1-M4 domains, thereby opening the hydrophobic gate and thereby allowing ions to pass. For example, the process may involve the activation of a monovalent Na + and K + Ions and Ca 2+ ion permeability. Advantageously, the ability of nAChR to alter intracellular calcium levels can lead to activation of different downstream intracellular pathways such as neuronal signaling and plasticity. In addition, the expression "mediate" can be understood to include facilitating intracellular signaling, for example through a G protein binding cluster contained in the intracellular loop of the α7 subunit.

[0065] Optionally, the compounds described herein, such as compounds of formula (I), can desensitize nAChR. Therefore, the compounds described herein, such as compounds of formula (I), can be suitable for desensitizing nAChR. Therefore, a compound described herein, such as a compound of formula (I), is also provided for use as a nAChR desensitizer.

[0066] More specifically, nAChRs can rapidly transition to a closed state upon activation, followed by a desensitized state. Desensitization is the loss of a biological response due to agonist stimulation. Upon washout of the ligand, the receptor can return to the basal or resting allosteric state.

[0067] According to the present invention, there is also provided use of the compounds described herein in the manufacture of a medicament for treating a disease or condition, such as use of a compound of formula (I) in the manufacture of a medicament for treating a disease or condition.

[0068] According to the present invention, there is also provided a method for treating a disease or condition, comprising the step of administering a compound described herein or a pharmaceutical composition described herein to a patient in need thereof. For example, there is provided a method for treating a disease or condition, comprising the step of administering a compound of formula (I) or a pharmaceutical composition comprising a compound of formula (I) to a patient in need thereof. For example, a method for treating a disease or condition may include the step of administering 4-(6-phenyl-3-pyridyl)-1-azabicyclo[3.2.2]non-3-ene or a pharmaceutical composition described herein to a patient in need thereof.

[0069] Optionally, the disease or condition is a disease or condition mediated by α7 nAChR.

[0070] Optionally, the disease or disorder is selected from: cognitive and neurodegenerative diseases; psychiatric disorders, such as schizophrenia; acute nociceptive, neuropathic or inflammatory pain; and affective disorders, such as depression and agitation.

[0071] For example, the disease or condition may be selected from:

[0072] i) pain, including one or more of acute pain, neuropathic pain, inflammatory pain, neuropathic pain, chronic pain, severe chronic pain, postoperative pain, cancer-related pain, angina, renal or biliary colic, menstrual pain, migraine, gout, arthritis, rheumatoid arthritis, tenosynovitis, vasculitis, trigeminal or herpetic neuralgia, diabetic neuropathy pain, causalgia, low back pain, deafferentation syndrome, and brachial plexus avulsion;

[0073] ii) metabolic syndrome, weight gain, type I diabetes, type II diabetes, or diabetic neuropathy;

[0074] iii) inflammation, including one or more of psoriasis, asthma, atherosclerosis, idiopathic pulmonary fibrosis, chronic and acute inflammation, psoriasis, endotoxemia, gout, acute pseudogout, acute gouty arthritis, arthritis, rheumatoid arthritis, osteoarthritis, allograft rejection, chronic transplant rejection, asthma, atherosclerosis, mononuclear phagocyte-dependent lung injury, atopic dermatitis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, acute chest syndrome in sickle cell disease, inflammatory bowel disease, Crohn's disease, ulcerative colitis, acute cholangitis, aphthous stomatitis, pouchitis, glomerulonephritis, lupus nephritis, thrombosis, and graft-versus-host reaction; and / or

[0075] iv) cognition, including one or more of age-related memory impairment, mild cognitive impairment, precocious dementia, early-onset Alzheimer's disease, senile dementia, Alzheimer's type dementia, mild to moderate Alzheimer's type dementia, Lewy body dementia, vascular dementia, Alzheimer's disease, stroke, AIDS dementia complex, attention deficit disorder, attention deficit hyperactivity disorder, dyslexia, schizophrenia, schizophreniform disorder, schizoaffective disorder, cognitive deficits in schizophrenia patients, and cognitive dysfunction in schizophrenia patients.

[0076] The pharmaceutical compositions may be used to ameliorate any symptoms associated with these conditions, diseases and disorders.

[0077] Preferably, the treatment is used to prevent and / or suppress cough, cough progression, improve cough symptoms and improve cough recurrence. Treatment can be used to treat the source of cough. Hereinafter, "cough" is understood to refer to the discharge of air from the lungs, for example, the discharge of air from the lungs of a subject (e.g., a human subject). Advantageously, the compounds of the present invention, such as compounds of formula (I), can be used as antitussives. Therefore, there is also provided a compound described herein for use as an antitussive, such as a compound of formula (I) for use as an antitussive. More specifically, antitussives can suppress coughs by a central mechanism or a peripheral mechanism or a mixture of the two mechanisms.

[0078] The pharmaceutical compositions described herein can be used as selective α7nAChR agonists. The pharmaceutical compositions described herein can also be used as antitussives. The pharmaceutical compositions described herein can also be used as anti-inflammatory agents, for example, for acute lung injury, allergen attack and / or Gram-negative bacterial infection. Therefore, the pharmaceutical compositions described herein can be used to treat inflammation, for example, for the treatment of acute lung injury, the treatment of allergen attack and / or the treatment of Gram-negative bacterial infection.

[0079] The compounds described herein may also be used as adjunctive therapy in conjunction with existing therapies, for example, for the management of any of the aforementioned types of diseases and conditions. In such cases, it is preferred to minimize the effects on nAChRs.

[0080] The active ingredient can be administered in a manner that affects only certain subtypes of the nervous system, such as those associated with muscles and ganglia. This can be achieved by targeted drug delivery and / or by adjusting the dose so that the desired effect is achieved without reaching a threshold dose required to achieve significant side effects.

[0081] Optionally, the compound for use, use or method according to the present description may be an orally administered compound.

[0082] Optionally, the compound for use, use or method according to the present invention may be administered in the form of a dry powder. Preferably, the compound is a dry powder 4-(6-phenyl-3-pyridyl)-1-azabicyclo[3.2.2]non-3-ene, such as dry powder insufflated 4-(6-phenyl-3-pyridyl)-1-azabicyclo[3.2.2]non-3-ene.

[0083] Optionally, the compound for use, use or method according to the present invention may be to administer the compound in aerosolized form. Preferably, the compound is aerosolized 4-(6-phenyl-3-pyridyl)-1-azabicyclo[3.2.2]non-3-ene.

[0084] Optionally, the compound for use, use or method according to the present description may be to administer the compound orally at a dose of 0.1 mg to 1 g / kg / day.

[0085] For example, the compound can be orally administered at a dosage of at least about 0.00001 mg / kg / day, at least about 0.0001 mg / kg / day, at least about 0.001 mg / kg / day, at least about 0.01 mg / kg / day, at least about 0.1 mg / kg / day, at least about 0.2 mg / kg / day, at least about 0.3 mg / kg / day, at least about 0.4 mg / kg / day, at least about 0.5 mg / kg / day. The compound can include any range of given endpoints.

[0086] For example, the compound can be administered orally at a dosage of no more than about 0.01 g / kg / day, no more than about 0.1 g / kg / day, no more than about 0.5 g / kg / day, no more than about 0.9 g / kg / day, no more than about 1 g / kg / day, no more than about 1.1 g / kg / day, no more than about 1.2 g / kg / day, no more than about 1.5 g / kg / day, no more than about 2 g / kg / day. The compound can include any range of given endpoints.

[0087] For example, the compound can be orally administered at a dosage of at least about 0.00001 mg / kg / day to no more than about 2 g / kg / day, at least about 0.0001 mg / kg / day to no more than about 1.5 g / kg / day, at least about 0.001 mg / kg / day to no more than about 1.2 g / kg / day, at least about 0.01 mg / kg / day to no more than about 1.1 g / kg / day, at least about 0.1 mg / kg / day to no more than about 1 g / kg / day, at least about 0.2 mg / kg / day to no more than about 0.9 g / kg / day, at least about 0.3 mg / kg / day to no more than about 0.5 g / kg / day, at least about 0.4 mg / kg / day to no more than about 0.1 g / kg / day, at least about 0.5 mg / kg / day to no more than about 0.01 g / kg / day. The compound can include any range of given endpoints.

[0088] For example, the compounds for use, uses or methods described herein can be administered at 0.1 mg / kg / day, 0.2 mg / kg / day, 0.3 mg / kg / day, 0.4 mg / kg / day, 0.5 mg / kg / day, 1 mg / kg / day, 2 mg / kg / day, 3 mg / kg / day, 4 mg / kg / day, 5 mg / kg / day, 10 mg / kg / day, 15 mg / kg / day, 20 mg / kg / day, 25 mg / kg / day, 30 mg / kg / day, 35 mg / kg / day, 40 mg / kg / day, 45 mg / kg / day, 50 mg / kg / day, 100 mg / kg / day, 150 mg / kg / day, 200 mg / kg / day, 250 mg / kg / day, 300 mg / kg / day, 350 mg / kg / day In some embodiments, the compound may be administered orally at 400 mg / kg / day, 500 mg / kg / day, 550 mg / kg / day, 600 mg / kg / day, 650 mg / kg / day, 700 mg / kg / day, 750 mg / kg / day, 800 mg / kg / day, 850 mg / kg / day, 900 mg / kg / day, 950 mg / kg / day, 1000 mg / kg / day, 1100 mg / kg / day, 1200 mg / kg / day, 1300 mg / kg / day, 1400 mg / kg / day, 1500 mg / kg / day, 1600 mg / kg / day, 1700 mg / kg / day, 1800 mg / kg / day, 1900 mg / kg / day, 2000 mg / kg / day. The compound may include any range of given endpoints.

[0089] Optionally, the compound for use, use or method described herein may be for oral administration of the compound at 5 mg to 2 g / day.

[0090] For example, the compound can be administered orally at a dosage of at least about 0.1 mg / day, at least about 1 mg / day, at least about 3 mg / day, at least about 4 mg / day, at least about 5 mg / day, at least about 5.1 mg / day, at least about 6 mg / day, at least about 10 mg / day, at least about 50 mg / day. The compound can include any range of given endpoints.

[0091] For example, the compound can be administered orally at a dosage of no more than about 0.2 g / day, no more than about 0.5 g / day, no more than about 1 g / day, no more than about 1.5 g / day, no more than about 2 g / day, no more than about 2.5 g / day, no more than about 3 g / day, no more than about 5 g / day, no more than about 10 g / day. The compound can include any range of given endpoints.

[0092] For example, the compound can be orally administered at a dosage of at least about 0.1 mg / day to no more than about 10 g / day, at least about 1 mg / day to no more than about 5 g / day, at least about 3 mg / day to no more than about 3 g / day, at least about 4 mg / day to no more than about 2.5 g / day, at least about 5 mg / day to no more than about 2 g / day, at least about 5.1 mg / day to no more than about 1.5 g / day, at least about 6 mg / day to no more than about 1 g / day, at least about 10 mg / day to no more than about 0.5 g / day, at least about 50 mg / day to no more than about 0.2 g / day. The compound can include any range of given endpoints.

[0093] For example, the compound can be administered at 1 mg / day, 2 mg / day, 3 mg / day, 4 mg / day, 5 mg / day, 6 mg / day, 7 mg / day, 8 mg / day, 9 mg / day, 10 mg / day, 11 mg / day, 12 mg / day, 13 mg / day, 14 mg / day, 15 mg / day, 20 mg / day, 25 mg / day, 30 mg / day, 35 mg / day, 40 mg / day, 45 mg / day, 50 mg / day, 100 mg / day, 150 mg / day, 200 mg / day, 250 mg / day, 300 mg / day, 350 mg / day, 400 mg / day, 450 mg / day, 500 mg / day The compound can be administered orally at a dosage of 500 mg / day, 600 mg / day, 650 mg / day, 700 mg / day, 750 mg / day, 800 mg / day, 850 mg / day, 900 mg / day, 950 mg / day, 1000 mg / day, 1100 mg / day, 1200 mg / day, 1300 mg / day, 1400 mg / day, 1500 mg / day, 1600 mg / day, 1700 mg / day, 1800 mg / day, 1900 mg / day, 2000 mg / day, 2100 mg / day, 2200 mg / day, 2300 mg / day, 2400 mg / day, 2500 mg / day. The compound can include any range of given endpoints.

[0094] The expression "about" with respect to numerical values ​​is to be understood as meaning ±10%, preferably ±5%, for example ±10% w / w, preferably ±5% w / w.

[0095] Optionally, the compounds, uses or methods described herein for use may be a composition in the form of a tablet. The tablet may be a film-coated tablet. The compounds, uses or methods described herein for use may be a composition in the form of a capsule, such as a gelatin capsule.

[0096] Optionally, the compound for use, use or method described herein may be for parenteral, topical, rectal, transmucosal or enteral administration of the compound.

[0097] According to the present invention, there is also provided a method for preparing a compound of general formula (I), as shown in scheme (I):

[0098]

[0099] Optionally, R 1 and R 2 As defined above, for example, for compounds of formula (I), R 1 and R 2 each is an optionally substituted aryl group which may be the same or different, wherein one or both aryl groups contain a carbocyclic or heterocyclic aromatic ring and one or both aryl groups are monocyclic or polycyclic, and wherein R 1 and R 2 is optionally fused. Alternatively, for compounds of formula (I), R 1 is optionally substituted aryl or optionally substituted heteroaryl, and R 2 is halogen, triflate, optionally substituted aryl, optionally substituted heteroaryl or absent.

[0100] As will be apparent to those skilled in the art, compounds of formula (I) include 4-substituted 1-azabicyclo[3.2.2]non-3-enes. Although the methods by which the compounds of the present invention may be prepared may vary, it may be advantageous to use intermediates generated during the synthesis of the target compounds to prepare the compounds, as shown in Scheme (I) above.

[0101] Although other synthetic strategies will be apparent to those skilled in the art, aryl substituted 1-azabicyclo[3.2.2]non-3-enes can be prepared starting from quinuclidine-3-one. A Büchner–Curtius–Schlotterbeck reaction can be used to promote one carbon ring expansion of the quinuclidine-3-one after triflation and Suzuki coupling with an aryl halide. Various combinations of aryl groups in formula (I) can be achieved via Suzuki cross-coupling reactions.

[0102] Specific examples of compounds

[0103] Examples of representative compounds of the present invention include, but are not limited to, the following compounds:

[0104] 4-(3-Pyridyl)-1-azabicyclo[3.2.2]non-3-ene

[0105]

[0106] 4-(6-phenyl-3-pyridyl)-1-azabicyclo[3.2.2]non-3-ene

[0107] and

[0108] 4-(6-phenylpyridazin-3-yl)-1-azabicyclo[3.2.2]non-3-ene

[0109]

[0110] Numbered paragraphs

[0111] Various aspects of the invention are described in the following numbered paragraphs:

[0112] 1. A compound of general formula (I):

[0113]

[0114] or a pharmaceutically acceptable salt thereof,

[0115] Where R 1 and R 2 each is an optionally substituted aryl group which may be the same or different, wherein one or both aryl groups contain a carbocyclic or heterocyclic aromatic ring and wherein one or both aryl groups are monocyclic or polycyclic,

[0116] And where R 1 and R 2 It is optionally fused.

[0117] 2. A compound according to numbered paragraph 1, wherein the or each of the carbocyclic or heterocyclic aromatic rings of one or both aryl groups is a 3- to 10-membered ring, such as a 5-membered ring or a 6-membered ring.

[0118] 3. A compound according to numbered paragraph 1 or numbered paragraph 2, wherein one or both aryl groups are monocyclic.

[0119] 4. A compound according to numbered paragraph 3, wherein one or two aryl groups are independently selected from the group consisting of phenyl, furanyl, pyrrolyl, thienyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, oxazolyl, oxadiazolyl, isoxazolyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl and thiadiazolyl.

[0120] 5. A compound according to any one of numbered paragraphs 1 or 2, wherein one or both aryl groups are polycyclic.

[0121] 6. A compound according to numbered paragraph 5, wherein one or two aryl groups are independently selected from the group consisting of naphthyl, anthracenyl, indolizinyl, indolyl, isoindolyl, benzofuranyl, benzothiophenyl, benzodioxolanyl, indazolyl, pyrrolopyridinyl, benzimidazolyl, benzothiazolyl, benzisothiazolyl, purinyl, thienopyrazinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, carbazolyl, acridinyl, naphthyridinyl, phenazinyl, phenothiazinyl, phenoxazinyl and azulenyl.

[0122] 7. A compound according to any preceding numbered paragraph, wherein one or both aryl groups are substituted, for example, by 1, 2 or 3 substituents.

[0123] 8. A compound according to numbered paragraph 7, wherein the substituents are independently selected from: alkyl, alkenyl, heterocyclyl, cycloalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, halogen (e.g., F, Cl, Br or I), --OR', --NR'R", --CF3, --CN, --NO2, --SR', --N3, --C(=O)NR'R", --NR'C(=O)R", --C(=O)R', -- C(=O)OR', --OC(=O)R', --O(CR'R"), --C(=O)R', --SO2R' and --SO2NR'R", wherein R' and R" are each hydrogen, lower alkyl (e.g., linear or branched alkyl, including C1-C8, preferably C1-C5, such as methyl, ethyl or isopropyl), cycloalkyl, heterocyclyl, aryl or arylalkyl (such as benzyl), and wherein R' and R" are optionally combined to form a cyclic functional group.

[0124] 9. A compound according to numbered paragraph 8, wherein the substituents are independently selected from the group consisting of cyano, halogen, alkyl, haloalkyl, cycloalkyl, alkoxy, haloalkoxy, and alkylthio.

[0125] 10. A compound according to any preceding numbered paragraph, wherein R 1 Selected from: 1,3,4-thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl.

[0126] 11. A compound according to any preceding numbered paragraph, wherein R 2 Selected from indolyl, benzofuranyl, benzothiazolyl and phenyl.

[0127] 12. A compound according to any preceding numbered paragraph, wherein the compound is selected from:

[0128] 4-(3-pyridinyl)-1-azabicyclo[3.2.2]non-3-ene;

[0129] 4-(6-phenyl-3-pyridyl)-1-azabicyclo[3.2.2]non-3-ene; and

[0130] 4-(6-Phenylpyridazin-3-yl)-1-azabicyclo[3.2.2]non-3-ene.

[0131] 13. A compound according to numbered paragraph 12, wherein the compound is 4-(6-phenyl-3-pyridinyl)-1-azabicyclo[3.2.2]non-3-ene.

[0132] 14. A compound according to any preceding numbered paragraph, wherein the pharmaceutically acceptable salt is selected from one or more of the following: chlorides, bromides, sulfates, phosphates and nitrates; organic acid addition salts such as acetates, galactarates, propionates, succinates, lactates, glycolates, malates, tartrates, citrates, maleates, fumarates, methanesulfonates, p-toluenesulfonates, ascorbates; salts with acidic amino acids such as aspartates or glutamates, or hydrates or ethanol solvates.

[0133] 15. A compound of general formula (I):

[0134]

[0135] or a pharmaceutically acceptable salt thereof,

[0136] in:

[0137] R 1 is optionally substituted aryl or optionally substituted heteroaryl; and

[0138] R 2is halogen, triflate, optionally substituted aryl, optionally substituted heteroaryl or absent;

[0139] or where R 1 and R 2 Together they form an optionally substituted aryl or an optionally substituted heteroaryl.

[0140] 16. A pharmaceutical composition comprising a compound according to any one of numbered paragraphs 1 to 15 and a pharmaceutically or therapeutically acceptable excipient or carrier.

[0141] 17. A compound according to any one of numbered paragraphs 1 to 15 for use in treating a disease or condition.

[0142] 18. A compound according to any one of numbered paragraphs 1 to 15 for use in treating a disease or condition mediated by the alpha 7 nicotinic acetylcholine receptor (nAChR).

[0143] 19. Use of a compound according to any one of numbered paragraphs 1 to 15 in the manufacture of a medicament for treating a disease or condition.

[0144] 20. A method of treating a disease or condition comprising the step of administering to a patient in need thereof a compound according to any one of numbered paragraphs 1 to 15 or a pharmaceutical composition according to numbered paragraph 16.

[0145] 21. A compound for use in treating a disease or condition according to numbered paragraph 17 or numbered paragraph 18, a use according to numbered paragraph 19 or a method according to numbered paragraph 20, wherein the treatment is for preventing and / or inhibiting cough, cough progression, improving cough symptoms and improving cough recurrence.

[0146] 22. A compound for use in treating a disease or condition according to numbered paragraph 17 or numbered paragraph 18, a use according to numbered paragraph 19, or a method according to numbered paragraph 20, wherein the disease or condition is selected from: cognitive and neurodegenerative diseases; psychiatric disorders such as schizophrenia; acute nociceptive, neuropathic or inflammatory pain; and affective disorders such as depression and agitation.

[0147] 23. A compound, use or method for treating a disease or condition according to numbered paragraph 21 or numbered paragraph 22, wherein the compound is administered orally.

[0148] 24. A compound, use or method for treating a disease or condition according to numbered paragraph 23, wherein the compound is administered orally at a dose of 0.1 mg to 1 g / kg / day.

[0149] 25. A compound, use or method for treating a disease or condition according to numbered paragraph 23, wherein the compound is administered orally at a dose of at least about 0.00001 mg / kg / day, at least about 0.0001 mg / kg / day, at least about 0.001 mg / kg / day, at least about 0.01 mg / kg / day, at least about 0.1 mg / kg / day, at least about 0.2 mg / kg / day, at least about 0.3 mg / kg / day, at least about 0.4 mg / kg / day, at least about 0.5 mg / kg / day.

[0150] 26. A compound, use or method for treating a disease or condition according to numbered paragraph 23, wherein the compound is administered orally at a dosage of no more than about 0.01 g / kg / day, no more than about 0.1 g / kg / day, no more than about 0.5 g / kg / day, no more than about 0.9 g / kg / day, no more than about 1 g / kg / day, no more than about 1.1 g / kg / day, no more than about 1.2 g / kg / day, no more than about 1.5 g / kg / day, no more than about 2 g / kg / day.

[0151] 27. A compound, use or method for treating a disease or condition according to numbered paragraph 23, wherein the compound is administered orally at a dosage of at least about 0.00001 mg / kg / day to no more than about 2 g / kg / day, at least about 0.0001 mg / kg / day to no more than about 1.5 g / kg / day, at least about 0.001 mg / kg / day to no more than about 1.2 g / kg / day, at least about 0.01 mg / kg / day to no more than about 1.1 g / kg / day, at least about 0.1 mg / kg / day to no more than about 1 g / kg / day, at least about 0.2 mg / kg / day to no more than about 0.9 g / kg / day, at least about 0.3 mg / kg / day to no more than about 0.5 g / kg / day, at least about 0.4 mg / kg / day to no more than about 0.1 g / kg / day, at least about 0.5 mg / kg / day to no more than about 0.01 g / kg / day.

[0152] 28. A compound, use or method for treating a disease or condition according to numbered paragraph 23, wherein the compound is administered orally at 5 mg to 2 g / day.

[0153] 29. A compound, use or method for treating a disease or condition according to numbered paragraph 23, wherein the compound is administered orally at a dose of at least about 0.1 mg / day, at least about 1 mg / day, at least about 3 mg / day, at least about 4 mg / day, at least about 5 mg / day, at least about 5.1 mg / day, at least about 6 mg / day, at least about 10 mg / day, at least about 50 mg / day.

[0154] 30. A compound, use or method for treating a disease or condition according to numbered paragraph 23, wherein the compound is administered orally at a dosage of no more than about 0.2 g / day, no more than about 0.5 g / day, no more than about 1 g / day, no more than about 1.5 g / day, no more than about 2 g / day, no more than about 2.5 g / day, no more than about 3 g / day, no more than about 5 g / day, no more than about 10 g / day.

[0155] 31. A compound, use or method for treating a disease or condition according to numbered paragraph 23, wherein the compound is administered orally at a dosage of at least about 0.1 mg / day to no more than about 10 g / day, at least about 1 mg / day to no more than about 5 g / day, at least about 3 mg / day to no more than about 3 g / day, at least about 4 mg / day to no more than about 2.5 g / day, at least about 5 mg / day to no more than about 2 g / day, at least about 5.1 mg / day to no more than about 1.5 g / day, at least about 6 mg / day to no more than about 1 g / day, at least about 10 mg / day to no more than about 0.5 g / day, at least about 50 mg / day to no more than about 0.2 g / day.

[0156] 32. A compound, use or method for treating a disease or condition according to any one of numbered paragraphs 23 to 31, wherein the composition is in the form of a tablet.

[0157] 33. A compound, use or method for treating a disease or condition according to numbered paragraph 21 or numbered paragraph 22, wherein the compound is administered parenterally, topically, rectally, transmucosally or enterally.

[0158] 34. A method for making a compound of formula (I), as shown in Scheme (I):

[0159]

[0160] Where R 1 and R 2 As defined in any of numbered paragraphs 1 to 11 or 15. BRIEF DESCRIPTION OF THE DRAWINGS

[0161] FIG. 1 is a flow chart showing the evaluation of cough response in a cough model.

[0162] Figure 2 The arrangement of the bar graphs shows the effect of 4-(6-phenyl-3-pyridyl)-1-azabicyclo[3.2.2]non-3-ene on the cumulative number of citric acid-induced coughs.

[0163] Figure 3Arrangement of bar graphs showing the effect of 4-(6-phenyl-3-pyridyl)-1-azabicyclo[3.2.2]non-3-ene on the cough latency of citric acid-induced cough.

[0164] experiment

[0165] The synthetic examples of the compounds described in Examples 1-5 and the biologically active examples described in Examples 6 and 7 are provided to illustrate the present invention and should not be construed as limiting the scope thereof. In these examples, unless otherwise stated, all parts and percentages are by weight. The reaction yields are reported in molar percentages.

[0166] Example 1 (reference): 1-azabicyclo[3.2.2]nonan-4-one (cas: 30708-54-4)

[0167]

[0168] Quinuclidine-3-one (20.0 g, 159 mmol, 1.00 equiv) in tetrahydrofuran (120 mL) was added to a solution of trimethylsilyldiazomethane (2.00 M, 95.8 mL, 1.20 equiv) at 5 ° C. Methanol (70 mL) was then added, and the mixture was stirred at 25 ° C for 12 hours. TLC (dichloromethane / methanol = 10 / 1) showed that a major spot (Rf = 0.35) was detected. After adding acetic acid (100 drops), the mixture was poured into a sodium carbonate solution (100 mL) and the organic layer was separated. The aqueous layer was extracted with dichloromethane (200 mL * 3). The organic layers were combined, dried over Na2SO4, filtered and concentrated under reduced pressure. 1-azabicyclo[3.2.2]nonane-4-one (20.0 g, crude product) was obtained as a yellow oil. 1H NMR (400MHz, CDCl3): δ3.14-3.01(m,2H), 2.99-2.90(m,4H), 2.67-2.66(m,2H), 2.64-2.53(m,1H), 1.80-1.77(m,2H), 1.72-1.68(m,2H).

[0169] Example 2: 1-azabicyclo[3.2.2]non-3-en-4-yl trifluoromethanesulfonate

[0170]

[0171] To a solution of lithium dimethylamide (2.00 M, 23.3 mL, 1.30 equiv) in tetrahydrofuran (10 mL) was added a solution of 1-azabicyclo[3.2.2]nonane-4-one (5.00 g, 35.9 mmol, 1.00 equiv) in tetrahydrofuran (30 mL) at -78 °C and stirred at -78 °C for 30 minutes. To the mixture was then added a solution of bis(trifluoromethanesulfonyl)aniline (16.6 g, 46.7 mmol, 1.30 equiv) in tetrahydrofuran (5 mL). The reaction mixture was quenched by adding saturated NaHCO (10 mL) at 25 °C and then filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO, dichloromethane / methanol = 1 / 0 to 10 / 1). 1-Azabicyclo[3.2.2]non-3-en-4-yl trifluoromethanesulfonate (10.0 g, crude) was obtained as a yellow oil. 1H NMR (400 MHz, CDCl3): δ 5.65-5.63 (m, 1H), 3.62 (d, J=2.9 Hz, 2H), 3.15-3.05 (m, 4H), 2.48-2.47 (m, 1H), 2.24-2.21 (m, 2H), 1.88-1.84 (m, 2H).

[0172] Example 3: 4-(3-pyridyl)-1-azabicyclo[3.2.2]non-3-ene

[0173] A solution of 1-azabicyclo[3.2.2]non-3-en-4-yl trifluoromethanesulfonate (1.00 g, 3.69 mmol, 1.00 equiv), pyridine-3-boronic acid (679 mg, 5.53 mmol, 1.50 equiv), K2CO3 (1.53 g, 11.0 mmol, 3.00 equiv), Pd(dppf)Cl2 (134 mg, 184 μmol, 0.0500 equiv) in water (2 mL) and dioxane (10 mL) was stirred at 90° C. for 3 hours. The reaction mixture was filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, dichloromethane / methanol=1 / 0 to 5 / 1; (1% NH3·H2O)) and by preparative HPLC (basic conditions; column: Waters Xbridge150*25mm*5um; mobile phase: [water (0.05% v / v ammonium hydroxide)-ACN]; B%: 17%-45%, 10 min). 4-(3-pyridyl)-1-azabicyclo[3.2.2]non-3-ene (16.0 mg, 79.62 μmol, yield 2.16%, purity 99.67%) was obtained as a light yellow gum. 1H NMR (400MHz, CD3OD): δ8.49(d,J=2.0Hz,1H),8.38(dd,J=1.5,4.8Hz,1H),7.78(td,J=1.9,8.0Hz,1H),7.37(dd,J=4 .9,7.9Hz,1H),5.86(dt,J=1.5,3.1Hz,1H),3.75(d,J=3.1Hz,2H),3.13-3.07(m,4H),2.79-2.78(m,1H),2.18-2.13

[0174] (m,2H),2.06-2.02(m,2H). LCMS: m / z=201(M+1)+.

[0175] Example 4: 4-(6-phenyl-3-pyridyl)-1-azabicyclo[3.2.2]non-3-ene

[0176] To a solution of 1-azabicyclo[3.2.2]non-3-en-4-yl trifluoromethanesulfonate (500 mg, 1.84 mmol, 1.00 equiv) and 2-phenyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (570 mg, 2.03 mmol, 1.10 equiv) in water (2 mL) and dioxane (10 mL) was added K2CO3 (764 mg, 5.53 mmol, 3.00 equiv) and Pd(dppf)Cl2 (67.4 mg, 92.1 μmol, 0.0500 equiv). The mixture was stirred at 90°C for 10 hours. The reaction mixture was filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, dichloromethane / methanol = 1 / 0 to 10 / 1). 4-(6-phenyl-3-pyridyl)-1-azabicyclo[3.2.2]non-3-ene (150 mg, 529 umol, yield 28.7%, purity 97.1%) was obtained as a brown solid. 1H NMR (400 MHz, CD3OD): δ8.59 (s, 1H), 7.93-7.82 (m, 3H), 7.50-7.43 (m, 3H), 7.16-6.89 (m, 1H), 5.92 (s, 1H), 3.87 (d, J = 3.2 Hz, 2H), 3.26-3.20 (m, 4H), 2.91 (s, 1H), 2.26-2.09 (m, 4H). LCMS: m / z = 277 (M+1)+.

[0177] Example 5: 4-(6-phenylpyridazin-3-yl)-1-azabicyclo[3.2.2]non-3-ene

[0178] Step 1: To a solution of 1-azabicyclo[3.2.2]non-3-en-4-yl trifluoromethanesulfonate (0.500 g, 1.84 mmol, 1.00 equiv) and bis(pinacolato)diboron (467 mg, 1.84 mmol, 1.00 equiv) in dioxane (10 mL) were added potassium acetate (361 mg, 3.68 mmol, 2.00 equiv) and Pd(dppf)Cl2 (67.3 mg, 92.0 μmol, 0.0500 equiv). The mixture was stirred at 80°C for 12 hours. 3-Chloro-6-phenylpyridazine (420 mg, 2.21 mmol, 1.20 equiv.), K2CO3 (762 mg, 5.52 mmol, 3.00 equiv.) and Pd(dppf)Cl2 (67.3 mg, 92.0 μmol, 0.0500 equiv.) were added to the mixture and the mixture was stirred at 90 ° C for 3 hours. The reaction mixture was filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, dichloromethane / methanol=1 / 0 to 10 / 1). 4-(6-phenylpyridazine-3-yl)-1-azabicyclo[3.2.2]non-3-ene (50.8 mg, 177 μmol, yield 9.63%, purity 96.7%) was obtained as a gray solid. 1H NMR (400MHz, CD3OD): δ8.11-8.07(m,2H),7.93(d,J=9.0Hz,1H),7.57-7.54(m,2H),7.18-6.93(m,2H),6.43-6 .42(m,1H),4.03(d,J=3.3Hz,2H),3.65-3.64(m,1H),3.32-3.29(m,2H),3.28-3.26(m,2H),2.25-2.09(m,4H). LCMS: m / z=278(M+1)+.

[0179] Example 6: Biological Activity

[0180] The compounds described in Examples 3 to 5 competitively inhibit the binding of radiolabeled α-bungarotoxin to the human α7 nAChR subtype with equilibrium constant (Ki) values ​​ranging from 1 to 1000 nM.

[0181] Human recombinant nicotinic acetylcholine α7 receptors were expressed in SH-SY5Y cells. 20 μg portions of the membrane were incubated with 0.4 nM [125I]α-bungarotoxin in modified phosphate buffer pH 7.4 at 37°C for 120 minutes. Nonspecific binding was estimated in the presence of 1 μM α-bungarotoxin. The membrane was filtered and washed, and the filter was counted to determine the specifically bound [125I]α-bungarotoxin. IC was determined by nonlinear least squares regression analysis using MathIQTM (ID Business Solutions Ltd., UK) 50 The observed IC values ​​of the tested compounds were 50 The Cheng and Prusoff equation was used to calculate Ki values ​​using the concentration of radioligand used in the assay and the historical value of the KD of the ligand (0.40 nM [125I]α-bungarotoxin). For each compound tested in Table 1 below, Ki values ​​are shown in nM.

[0182] Table 1

[0183]

[0184] Example 7: In vivo cough induction experiment

[0185] Materials and methods

[0186] As shown in Figure 1, guinea pigs were placed in an TM Cough induction was performed in a whole body plethysmograph (WBP) with a vibrating mesh nebulizer and a pressure sensor and detection equipment (EMKA technologies). A primary microphone (EMKA Technologies) was provided to acoustically confirm cough frequency in the form of a digital trace using EMKA software. Data acquisition software (iOX2, version 2.10.5.28, EMKA Technologies, France) displays the pressure signal detected from the pressure sensor and calculates cough frequency and intensity measured during the test.

[0187] An auxiliary microphone (T1 True Wireless Earphone, ) and connected to a smartphone via Bluetooth to enable the observer to hear audible sounds during the test. A bias flow rate of 2 L / min was used to continuously draw atmospheric air (during the fresh air period) or aerosolized citric acid from the nebulizer into the WBP and expel it through the exhaust tube. The chamber pressure in the WBP was set between -10 and -30 Pa relative to ambient pressure.

[0188] Prior to citric acid challenge, guinea pigs were administered (ip) different doses of vehicle control, positive control or test compound (as applicable) (Table 2) and placed individually in WBP for at least 5 minutes to allow for acclimatization.

[0189] Table 2

[0190]

[0191] The procedure was as follows: injection → place mouse in box with citric acid for 10 minutes (count coughs) → then fill box with air for 5 minutes (count coughs) → move mouse to recovery cage.

[0192] Use appropriate concentration of citric acid to generate aerosol and deliver to WBP, continue 10 minutes, while constantly recording pressure measurements. The average concentration of citric acid is 1283.1 ± 137.2 μg / L. After completing the citric acid challenge, allow guinea pigs to recover and continue to record cough counts for another 5 minutes. Subsequently, closely monitor whether guinea pigs are fully recovered from the attack in the recovery cage and there are no adverse events before the animals are returned to their home cages. Starting from citric acid stimulation, record cough counts (CCnt) in a time period of at least 10 minutes, and cough latency (CIP) is defined as the time spent for the first cough after citric acid stimulation.

[0193] Carefully monitor cough response during citric acid challenge and post-treatment recovery using the following methods:

[0194] -Continuous pressure monitoring (plethysmography monitoring software)

[0195] - Acoustic confirmation of cough using microphones (primary and secondary)

[0196] -Visual confirmation of coughing by postural change.

[0197] Statistical analysis and data presentation

[0198] Data were analyzed using one-way ANOVA when compared to saline controls (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001), and each column represents the mean±SEM.

[0199] Figure 2 and Figure 3 The present invention relates to the evaluation of the antitussive efficacy of 4-(6-phenyl-3-pyridinyl)-1-azabicyclo[3.2.2]non-3-ene using an in vivo model of chemically induced cough in guinea pigs.

[0200] Respectively, Figure 2 A and 3A show mean ± SEM, while Figure 2B and 3B show the results for each replicate.

[0201] result

[0202] like Figure 2 As shown in the Figures 2A and 2B for cough counts, the exemplary compound of the present invention, 4-(6-phenyl-3-pyridinyl)-1-azabicyclo[3.2.2]non-3-ene, significantly reduced citric acid-induced cough counts when compared to saline controls.

[0203] More specifically, compared to the saline control (0.9% sodium chloride, cough count = 13), 4-(6-phenyl-3-pyridyl)-1-azabicyclo[3.2.2]non-3-ene significantly reduced citric acid-induced cough counts at low concentrations (1.5 mg / kg, cough count = 3, p<0.0001), medium concentrations (5 mg / kg, cough count = 6, p<0.05), and high concentrations (15 mg / kg, cough count = 7, p<0.05).

[0204] The reduction in citric acid-induced cough counts by 4-(6-phenyl-3-pyridinyl)-1-azabicyclo[3.2.2]non-3-ene was similar to that achieved by 30 mg / kg codeine. However, at 1.5 mg / kg to 15 mg / kg, the dose of 4-(6-phenyl-3-pyridinyl)-1-azabicyclo[3.2.2]non-3-ene was approximately 20 to 30 times lower than the 30 mg / kg dose of codeine.

[0205] In addition, if Figure 3 As shown in the latencies, 4-(6-phenyl-3-pyridinyl)-1-azabicyclo[3.2.2]non-3-ene showed a significant improvement in cough latency.

[0206] More specifically, 4-(6-phenyl-3-pyridinyl)-1-azabicyclo[3.2.2]non-3-ene significantly increased cough latency at low concentrations (1.5 mg / kg, 504 seconds, p<0.05) and high concentrations (15 mg / kg, 491 seconds, p<0.05) compared to saline controls (0.9% sodium chloride, 232 seconds).

[0207] The increase in cough latency with 4-(6-phenyl-3-pyridinyl)-1-azabicyclo[3.2.2]non-3-ene was similar to that with 30 mg / kg of codeine. However, at 1.5 mg / kg to 15 mg / kg, the dose of 4-(6-phenyl-3-pyridinyl)-1-azabicyclo[3.2.2]non-3-ene was approximately 20 to 30 times lower than the 30 mg / kg dose of codeine.

[0208] in conclusion

[0209] The exemplary compound of the present invention, 4-(6-phenyl-3-pyridinyl)-1-azabicyclo[3.2.2]non-3-ene, significantly reduced citric acid-induced cough counts when compared to saline controls (see Figure 2 ).

[0210] In addition, 4-(6-phenyl-3-pyridyl)-1-azabicyclo[3.2.2]non-3-ene also showed significant improvement in cough latency at doses approximately 20 to 30 times lower than codeine, which is considered the "gold standard" narcotic cough suppressant (see Figure 3 ).

Claims

1. A compound of general formula (I): or a pharmaceutically acceptable salt thereof, in R 1 is optionally substituted aryl or optionally substituted heteroaryl; and R 2 is halogen, triflate, optionally substituted aryl, optionally substituted heteroaryl or absent; or where R 1 and R 2 Together they form an optionally substituted aryl or an optionally substituted heteroaryl.

2. A compound according to claim 1, wherein the or each aryl or heteroaryl group is a 5- to 10-membered ring, such as a 5-membered ring or a 6-membered ring.

3. A compound according to claim 1 or claim 2, wherein one or both aryl or heteroaryl groups are monocyclic.

4. The compound of claim 3, wherein one or two aryl or heteroaryl groups are independently selected from the group consisting of phenyl, furanyl, pyrrolyl, thienyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, oxazolyl, oxadiazolyl, isoxazolyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl and thiadiazolyl.

5. A compound according to claim 1 or claim 2, wherein one or both aryl or heteroaryl groups are polycyclic.

6. The compound of claim 5, wherein one or two aryl or heteroaryl groups are independently selected from the group consisting of naphthyl, anthracenyl, indolizinyl, indolyl, isoindolyl, benzofuranyl, benzothienyl, benzodioxolanyl, indazolyl, pyrrolopyridinyl, benzimidazolyl, benzothiazolyl, benzisothiazolyl, purinyl, thienopyrazinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, carbazolyl, acridinyl, naphthyridinyl, phenazinyl, phenothiazinyl, phenoxazinyl and azulenyl.

7. A compound according to any preceding claim, wherein one or two aryl or heteroaryl groups are substituted, for example, by 1, 2 or 3 substituents, wherein optionally the substituents are independently selected from: alkyl, alkenyl, heterocyclyl, cycloalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, halogen (e.g., F, Cl, Br or I), --OR', --NR'R", --CF3, -CN, --NO2, --SR', --N3, --C(=O)NR'R", --NR'C (=O)R", --C(=O)R', --C(=O)OR', --OC(=O)R', --O(CR'R"), --C(=O)R', --SO2R' and --SO2NR'R", wherein R' and R" are each hydrogen, lower alkyl (e.g., linear or branched alkyl, including C1-C8, preferably C1-C5, such as methyl, ethyl or isopropyl), cycloalkyl, heterocyclyl, aryl or arylalkyl (such as benzyl), and wherein R' and R" are optionally combined to form a cyclic functional group.

8. The compound of claim 7, wherein the substituents are independently selected from the group consisting of cyano, halogen, alkyl, haloalkyl, cycloalkyl, alkoxy, haloalkoxy, and alkylthio.

9. A compound according to any preceding claim, wherein R 1 is selected from 1,3,4-thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, and / or wherein R 2 Selected from indolyl, benzofuranyl, benzothiazolyl and phenyl.

10. A compound according to any preceding claim, wherein the compound is selected from: 4-(3-pyridinyl)-1-azabicyclo[3.2.2]non-3-ene; 4-(6-phenyl-3-pyridinyl)-1-azabicyclo[3.2.2]non-3-ene; and 4-(6-phenylpyridazin-3-yl)-1-azabicyclo[3.2.2]non-3-ene, For example, the compound is 4-(6-phenyl-3-pyridyl)-1-azabicyclo[3.2.2]non-3-ene.

11. A pharmaceutical composition comprising a compound according to any one of claims 1 to 10 and a pharmaceutically or therapeutically acceptable excipient or carrier.

12. A compound according to any one of claims 1 to 10 for use in treating a disease or disorder.

13. A compound according to any one of claims 1 to 10 for use in the treatment of a disease or condition mediated by the alpha 7 nicotinic acetylcholine receptor (nAChR).

14. A compound for use in treating a disease or condition according to claim 12 or claim 13, wherein the treatment is for preventing and / or inhibiting cough, cough progression, improving cough symptoms and improving cough recurrence.

15. A method for preparing a compound of general formula (I), as shown in Scheme (I): Where R 1 and R 2 As defined in any one of claims 1 to 14.